213 related articles for article (PubMed ID: 24590045)
1. Supplementation of influenza split vaccines with conserved M2 ectodomains overcomes strain specificity and provides long-term cross protection.
Kim MC; Lee YN; Ko EJ; Lee JS; Kwon YM; Hwang HS; Song JM; Song BM; Lee YJ; Choi JG; Kang HM; Quan FS; Compans RW; Kang SM
Mol Ther; 2014 Jul; 22(7):1364-1374. PubMed ID: 24590045
[TBL] [Abstract][Full Text] [Related]
2. Co-immunization with tandem repeat heterologous M2 extracellular proteins overcomes strain-specific protection of split vaccine against influenza A virus.
Lee YN; Kim MC; Lee YT; Kim YJ; Lee J; Kim C; Ha SH; Kang SM
Antiviral Res; 2015 Oct; 122():82-90. PubMed ID: 26248203
[TBL] [Abstract][Full Text] [Related]
3. Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity.
Kim MC; Lee YN; Hwang HS; Lee YT; Ko EJ; Jung YJ; Cho MK; Kim YJ; Lee JS; Ha SH; Kang SM
Vaccine; 2014 Oct; 32(44):5824-31. PubMed ID: 25171841
[TBL] [Abstract][Full Text] [Related]
4. Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection.
Kim MC; Lee JW; Choi HJ; Lee YN; Hwang HS; Lee J; Kim C; Lee JS; Montemagno C; Prausnitz MR; Kang SM
J Control Release; 2015 Jul; 210():208-16. PubMed ID: 26003039
[TBL] [Abstract][Full Text] [Related]
5. Enhancing the cross protective efficacy of live attenuated influenza virus vaccine by supplemented vaccination with M2 ectodomain virus-like particles.
Lee YT; Kim KH; Ko EJ; Kim MC; Lee YN; Hwang HS; Lee Y; Jung YJ; Kim YJ; Santos J; Perez DR; Kang SM
Virology; 2019 Mar; 529():111-121. PubMed ID: 30685658
[TBL] [Abstract][Full Text] [Related]
6. Intranasal vaccination with M2e5x virus-like particles induces humoral and cellular immune responses conferring cross-protection against heterosubtypic influenza viruses.
Lee YT; Ko EJ; Lee Y; Kim KH; Kim MC; Lee YN; Kang SM
PLoS One; 2018; 13(1):e0190868. PubMed ID: 29324805
[TBL] [Abstract][Full Text] [Related]
7. Supplementation of H1N1pdm09 split vaccine with heterologous tandem repeat M2e5x virus-like particles confers improved cross-protection in ferrets.
Music N; Reber AJ; Kim MC; York IA; Kang SM
Vaccine; 2016 Jan; 34(4):466-473. PubMed ID: 26709639
[TBL] [Abstract][Full Text] [Related]
8. Supplementation of seasonal vaccine with multi-subtype neuraminidase and M2 ectodomain virus-like particle improves protection against homologous and heterologous influenza viruses in aged mice.
Raha JR; Kim KH; Bhatnagar N; Liu R; Le CTT; Park BR; Grovenstein P; Pal SS; Ko EJ; Shin CH; Wang BZ; Kang SM
Antiviral Res; 2024 May; 225():105877. PubMed ID: 38561077
[TBL] [Abstract][Full Text] [Related]
9. Vaccine Efficacy Induced by 2009 Pandemic H1N1 Virus-Like Particles Differs from that Induced by Split Influenza Virus.
Lee GJ; Chu KB; Inn KS; Moon EK; Quan FS
Immunol Invest; 2020 Oct; 49(7):781-793. PubMed ID: 31774021
[TBL] [Abstract][Full Text] [Related]
10. Crossprotection induced by virus-like particles containing influenza dual-hemagglutinin and M2 ectodomain.
Mao J; Eom GD; Yoon KW; Kim MJ; Chu KB; Kang HJ; Quan FS
Nanomedicine (Lond); 2024 Apr; 19(9):741-754. PubMed ID: 38390688
[No Abstract] [Full Text] [Related]
11. Supplemented vaccination with tandem repeat M2e virus-like particles enhances protection against homologous and heterologous HPAI H5 viruses in chickens.
Song BM; Kang HM; Lee EK; Jung SC; Kim MC; Lee YN; Kang SM; Lee YJ
Vaccine; 2016 Jan; 34(5):678-686. PubMed ID: 26691568
[TBL] [Abstract][Full Text] [Related]
12. Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus.
Song JM; Van Rooijen N; Bozja J; Compans RW; Kang SM
Proc Natl Acad Sci U S A; 2011 Jan; 108(2):757-61. PubMed ID: 21187388
[TBL] [Abstract][Full Text] [Related]
13. A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.
Wu CY; Yeh YC; Chan JT; Yang YC; Yang JR; Liu MT; Wu HS; Hsiao PW
PLoS One; 2012; 7(8):e42363. PubMed ID: 22879951
[TBL] [Abstract][Full Text] [Related]
14. Fc receptor is not required for inducing antibodies but plays a critical role in conferring protection after influenza M2 vaccination.
Lee YN; Lee YT; Kim MC; Hwang HS; Lee JS; Kim KH; Kang SM
Immunology; 2014 Oct; 143(2):300-9. PubMed ID: 24773389
[TBL] [Abstract][Full Text] [Related]
15. Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA).
Mu X; Hu K; Shen M; Kong N; Fu C; Yan W; Wei A
J Virol Methods; 2016 Feb; 228():84-90. PubMed ID: 26615805
[TBL] [Abstract][Full Text] [Related]
16. Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses.
Tao W; Hurst BL; Shakya AK; Uddin MJ; Ingrole RS; Hernandez-Sanabria M; Arya RP; Bimler L; Paust S; Tarbet EB; Gill HS
Antiviral Res; 2017 May; 141():62-72. PubMed ID: 28161578
[TBL] [Abstract][Full Text] [Related]
17. Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus.
Kim MC; Song JM; O E; Kwon YM; Lee YJ; Compans RW; Kang SM
Mol Ther; 2013 Feb; 21(2):485-92. PubMed ID: 23247101
[TBL] [Abstract][Full Text] [Related]
18. Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection.
Kim MC; Lee JS; Kwon YM; O E; Lee YJ; Choi JG; Wang BZ; Compans RW; Kang SM
Antiviral Res; 2013 Sep; 99(3):328-35. PubMed ID: 23811283
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
[TBL] [Abstract][Full Text] [Related]
20. Co-Delivery of M2e Virus-Like Particles with Influenza Split Vaccine to the Skin Using Microneedles Enhances the Efficacy of Cross Protection.
Kim MC; Kim KH; Lee JW; Lee YN; Choi HJ; Jung YJ; Kim YJ; Compans RW; Prausnitz MR; Kang SM
Pharmaceutics; 2019 Apr; 11(4):. PubMed ID: 31003421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
